The UK-based pharmaceutical and healthcare company has hired members for the new team to further expand its product R&D division
[L-R]: Head of Microbiology, Annaliese Waite, and Microbiologist, Heather Lloyd
SpectrumX, a healthcare and pharmaceutical company, has created an in-house microbiology team to further the company’s strategy to expand its product R&D division.
The UK-based company has appointed a Head of Microbiology, Annaliese Waite, BSc, and Microbiologist Heather Lloyd, MSc, LIBMS (Licentiate of the Institute of Biomedical Science). These appointments form a new microbiology team at SpectrumX.
Waite brings extensive microbiology experience at large pharmaceutical companies, including AstraZeneca, where she developed rapid sterility testing for the COVID-19 vaccine.
These appointments signal our intention to build out our product R&D team and illustrate our commitment to quickly and efficiently bring our products to market
Most recently, Waite was a member of the technical team at Byotrol, an antimicrobial technologies company, where she focused on R&D, including microbiological testing and conducting preparatory procedures to ensure quality standards.
At SpectrumX, Waite will apply her industry expertise to expand the company’s product R&D capabilities through developing testing methods, managing its laboratories, and preparing a quality control programme for SpectrumX’s products. This will allow the company to more seamlessly implement necessary regulatory procedures in preparation for market authorisation.
Lloyd is experienced in assessing antimicrobial efficacy of both industrial and cosmetic product samples, most recently as a microbiologist at Thor Specialities, a multinational manufacturer and distributor of biocides, flame retardants, personal care ingredients, and other speciality chemicals.
Lloyd’s efficacy testing expertise will inform and enhance the development and production of SPX-001, SpectrumX’s prospective antipathogenic medicinal treatment that contains the company’s patent-pending formulation of hypochlorous acid (HOCl). She also brings a particular interest and background in antimicrobial resistance research, in which HOCl has shown early promise in efficacy.
Damien Hancox, CEO of SpectrumX, said: “We are pleased to have appointed Annaliese and Heather to expand our product R&D capabilities at SpectrumX. The wealth of knowledge and insight these talented individuals bring will support us on the path to commercialising our products. These appointments signal our intention to build out our product R&D team and illustrate our commitment to quickly and efficiently bring our products to market.”